Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule

Biotech firm grants stock options and restricted stock units to new hires

Apr. 2, 2026 at 7:20am

Got story updates? Submit your updates here. ›

Vor Bio, a clinical-stage biotechnology company focused on autoimmune diseases, announced that on April 1, 2026, the Compensation Committee of its Board of Directors granted stock options and restricted stock units (RSUs) to 9 newly hired employees as material inducements to employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters

Inducement grants like these are common practice for public companies to attract and retain top talent, especially in competitive industries like biotech. The grants provide employees with equity incentives aligned with shareholder interests and help Vor Bio build out its team as it advances its lead drug candidate, telitacicept, through late-stage clinical trials.

The details

The stock options have a 10-year term and an exercise price of $17.39 per share, equal to Vor Bio's closing price on the grant date. The options will vest over 4 years, with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months. The RSUs will also vest over 4 years, with 25% vesting after 12 months and the remaining shares vesting quarterly over the following 36 months. All grants are subject to the employees' continued employment with Vor Bio.

  • The grants were made on April 1, 2026.

The players

Vor Bio

A clinical-stage biotechnology company transforming the treatment of autoimmune diseases, focused on advancing its lead drug candidate telitacicept.

Compensation Committee

The committee of Vor Bio's Board of Directors that approved the inducement grants to the 9 new hires.

Got photos? Submit your photos here. ›

The takeaway

Vor Bio's inducement grants to new hires demonstrate the company's commitment to building a strong team as it progresses its pipeline of autoimmune disease treatments. These types of equity incentives are common practice for public biotech firms looking to attract top talent in a competitive industry.